Who is sponsoring NCT05638529?

NCT05638529 is sponsored by Mount Sinai Hospital, Canada.

What drugs are being tested in NCT05638529?

Interventions in NCT05638529: Pregnyl (1,500) IU, 1.5 mL of normal saline.

What condition does NCT05638529 study?

NCT05638529 studies Ovarian Hyperstimulation Syndrome, Infertility, Female.

Is NCT05638529 still recruiting?

NCT05638529 is currently status unknown. Last updated 3 July 2023.

Last reviewed 2023-07-03 · How we verify

NCT05638529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome

Status unknown Phase 4 Last updated 3 July 2023

What this trial tests

Phase 4 trial testing Pregnyl (1,500) IU in Ovarian Hyperstimulation Syndrome in 80 participants. Status unknown.

Timeline

1 May 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Mount Sinai Hospital, Canada
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	1 May 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Canada

Drugs / interventions tested

Pregnyl (1,500) IU — full drug profile →
1.5 mL of normal saline — full drug profile →

Conditions studied

Ovarian Hyperstimulation Syndrome — all drugs for Ovarian Hyperstimulation Syndrome →
Infertility, Female — all drugs for Infertility, Female →

Sponsor

Mount Sinai Hospital, Canada

Who can join

Adults 18 to 40, female only, with Ovarian Hyperstimulation Syndrome or Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to evaluate whether the use of a "dual trigger" can improve IVF outcomes, compared to GnRH agonist (GnRH-a) alone, in patients at high risk of OHSS undergoing a freeze-all cycle. By examining freeze-all cycles with frozen embryo transfer(s) (FET) only, we eliminate the potential confounding issue of inadequate luteal support to the endometrium and focus primarily on the effect of a "dual trigger" on oocyte quality and embryo potential. To our best knowledge, there have been no randomized, controlled trials conducted to address this hypothesis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mount Sinai Hospital, Canada trials

Trials by the same sponsor.

NCT07272460 — Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial · NA · recruiting
NCT07046572 — Methoxyflurane for IUD Insertion and Endometrial Biopsy · NA · recruiting
NCT06504277 — Low Versus Standard Pressure Pneumoperitoneum on Shoulder Tip Pain · NA · recruiting
NCT06546254 — 1% Lidocaine Paracervical Block for Endometrial Biopsy · NA · completed
NCT06733701 — The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05638529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mount Sinai Hospital, Canada
Last refreshed: 3 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing